A phase IB, open label, single center, drug-drug interaction study of oral 1250 mg of PTK787/ZK 222584 [vatalanib] administered under fasting and fed conditions with a proton-pump inhibitor (omeprazole) in healthy sterile or postmenopausal female volunteers.

Trial Profile

A phase IB, open label, single center, drug-drug interaction study of oral 1250 mg of PTK787/ZK 222584 [vatalanib] administered under fasting and fed conditions with a proton-pump inhibitor (omeprazole) in healthy sterile or postmenopausal female volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Sep 2009

At a glance

  • Drugs Vatalanib (Primary) ; Omeprazole
  • Indications Age-related macular degeneration; Colorectal cancer; Gastro-oesophageal reflux; Glioblastoma; Multiple myeloma; Non-small cell lung cancer; Ovarian cancer; Renal cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 17 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top